Insight Molecular Diagnostics, Inc. is a diagnostics technology company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The company was founded in September 2009 and is headquartered in Nashville, TN.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
58
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Insight Molecular Diagnostics Inc. market cap is $64.53M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Insight Molecular Diagnostics Inc. 52 week high is $7.51 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Insight Molecular Diagnostics Inc. 52 week low is $1.50 as of November 22, 2026.
Insight Molecular Diagnostics Inc. stock price today is $1.97.
Insight Molecular Diagnostics Inc. stock price yesterday was $1.66.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Insight Molecular Diagnostics Inc.'s P/E ratio is -1.58.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Insight Molecular Diagnostics Inc. P/B ratio is -2.6691.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Insight Molecular Diagnostics Inc. 50-day moving average is $3.05.
Insight Molecular Diagnostics Inc. has 58 employees.